REG - Abingdon Health PLC - £4.8m contracts awarded

Abingdon HealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260330:nRSd5354Ya&default-theme=true

RNS Number : 5354Y  Abingdon Health PLC  30 March 2026

This announcement contains inside information for the purposes of Article 7 of
the UK version of Regulation (EU) No 596/2014 which is part of UK law by
virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the
publication of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public domain.

 

 

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

£4.8m contracts awarded for development of multiplex lateral flow systems

 

York, U.K. 30 March 2026: Abingdon Health plc (AIM: ABDX), a leading
international developer, manufacturer and regulatory services provider for
rapid diagnostic tests and med-tech, announces that it has been awarded a
series of significant contracts with a USA-based customer to develop, and
scale up to manufacture several multiplex quantitative lateral flow assay
systems measuring multiple biomarkers simultaneously in human samples. The
contracts include full programme management, the management of regulatory
processes, and analytical and clinical performance services.

 

The contracts have a total value of approximately £4.8 million based on the
agreed scope of work and will be delivered over a circa 27-month period
commencing immediately. These contracts will be executed via a series of work
packages based on agreed milestones, with potential further scope beyond that
period including appointment as legal manufacturer. The contracts represent an
important validation of Abingdon Health's full programme management CDMO
service which offers development from feasibility and initial regulatory
pathway provision through to product manufacture and multi-territory
regulatory approvals.

 

The programmes of work will leverage the Group's established and growing
capabilities in lateral flow test development and manufacture in its York, UK
and Madison, Wisconsin, USA facilities. In addition, the programmes will
utilise its regulatory services companies, CS Lifesciences and IVDeology, as
well as analytical and clinical performance evaluation services provided by
Abingdon Analytical at its Doncaster, UK facilities. It underscores Abingdon
Health's position as a leading provider of integrated CDMO/CRO services for
rapid diagnostic tests and med-tech.

 

Dr Chris Hand, Executive Chairman, commented: "We are delighted to announce
these significant contract awards. Our multi-disciplinary teams of highly
skilled in-house experts in the fields of immunodiagnostics, lateral flow
development and manufacture, regulatory approvals, performance evaluation, and
programme management continue to resonate with our customers. These contract
wins reinforce our position as the 'go-to' experts for the provision of
end-to-end lateral flow test development and programme management: in this
case for complex multiplex quantitative test devices."

 

LEI - 213800XFI4WV3FBILO20

 

Enquiries:

 

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                                         Via Walbrook PR
 Tom Hayes, CFO

 Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)                    Tel: +44 (0)20 7220 0500
 Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health

 

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
(Contract Development and Manufacturing Organisation) expertise offers lateral
flow product development, regulatory support, technology transfer and
manufacturing services for customers looking to develop new assays or transfer
existing laboratory-based assays to a lateral flow format.  Abingdon Health
has the internal capabilities to take lateral flow projects, in areas such as
infectious disease and clinical testing, including companion diagnostics,
animal health and environmental testing, from initial concept through to
routine manufacturing; from idea to commercial success.

 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences)
and IVDeology, provide a broad range of regulatory services to the in vitro
diagnostic and wider medical device industry, to support customers in bringing
products to market across a range of territories including the USA, EU and the
UK. Its consultancy services range from design, implementation and maintenance
of quality management systems, preparation of technical files for regulatory
approvals, part-time and interim management support, auditing both internal
and external, management reviews and presentations, training and mentoring.
 The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing
and performance evaluation to generate the required technical and data for
regulatory approval for lateral flow and other in vitro diagnostic assays from
its Doncaster, England facilities.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
 outlines the comprehensive support the Group can now provide to its
international customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTSEISAUEMSEFD



            Copyright 2019 Regulatory News Service, all rights reserved